Deirdre Cohen named director of Mount Sinai’s Gastrointestinal Oncology Program

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Deirdre J. Cohen, an expert in pancreatic and other gastrointestinal cancers, was named director of the Gastrointestinal Oncology Program and medical director of the Cancer Clinical Trials Office at The Tisch Cancer Institute at Mount Sinai Health System.

Cohen will also be an associate professor of medicine (hematology and medical oncology) at the Icahn School of Medicine at Mount Sinai. In these roles, she will conduct translational and clinical research, including studies that build upon scientific discoveries developed at Mount Sinai and collaborating institutions.

As director of the GI Oncology Program, Cohen will foster both clinical and research activities associated with GI cancers across the Mount Sinai cancer sites. She will also oversee the development of clinical trials in her role as medical director of the Cancer Clinical Trials Office.

Prior to joining Mount Sinai, Cohen was on the faculty in the Division of Medical Oncology at New York University for 13 years. Recently, she served as medical director for the Perlmutter Cancer Center Clinical Trials Office and acting director of NYU GI Medical Oncology.

Table of Contents

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login